Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
Clinical trial NCT07470489 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07470489
- Sponsor
- M.D. Anderson Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-30
- Primary completion
- 2030-09-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.